Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nalmefene in Pathological Gambling
NCT00132119Phase 3Completed
- Sponsor
- Somaxon Pharmaceuticals, Inc.
- Start
- Aug 2005
- Primary completion
- Aug 2006
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of nalmefene in gambling disorder (GD) (3 arms), sponsored by Somaxon Pharmaceuticals, Inc. Primary endpoint: Yale-Brown Obsessive Compulsive Scale Modified for Pathological Gambling at 10 weeks. Started Aug 2005; status: completed.
02
Drugs
nalmefene
03
Conditions
gambling disorder (GD)
Beyond the preview
Go deeper on NCT00132119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00132119.